XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Additional Information (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2021
Feb. 23, 2021
Verve Therapeutics, Inc.      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Equity securities $ 18.8    
Verve Therapeutics, Inc. | Common Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Equity shares held 546,970 546,970  
Technology Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Potential milestone payable in form of common stock     $ 100.0
Product Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Potential milestone payable in form of common stock     $ 220.0